Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway.
Feng J, Xu R, Dou Z, Hao Y, Xu R, Khoso MA, Shi Y, Liu L, Sun H, Chen C, Li X, Liu H, Han W, Cheng M, Tang P, Li J, Zhang Y, Liu X.
Feng J, et al.
Eur J Pharmacol. 2025 Jan 2:177228. doi: 10.1016/j.ejphar.2024.177228. Online ahead of print.
Eur J Pharmacol. 2025.
PMID: 39755242